Health care can benefit from the streamlined FDA authorization processes used during the pandemic, former FDA Principal Deputy Commissioner Amy Abernethy said, but the agency needs to do a better job collecting postmarket data and communicating with the public. Accelerated authorization of COVID-19 vaccines during the pandemic demonstrated that FDA could continue to evaluate the data on a product after initial authorization, Abernethy said Tuesday (Nov. 15) at the HLTH Conference in Las Vegas. “What that story told us is...